NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 200 participants.
Also called NCT04055428
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 200 participants
- Registry
-
NCT04055428
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT04055428. Randomized; quadruple masking; primary purpose treatment. Start 2020-08-15 (actual); primary completion 2026-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals
- Condition
- Diabetes Mellitus
- Condition
- Cardiovascular Diseases
- Condition
- Insulin Sensitivity/Resistance
- Condition
- Metabolic Disease
- Condition
- Natriuretic Peptides
- Condition
- Metabolism
- Condition
- Energy Expenditure
- Intervention (Drug)
- Sacubitril, Valsartan 97-103 mg Oral Tablet
- Intervention (Drug)
- Valsartan 160 mg
- Intervention (Other)
- Intravenous Glucose Tolerance Test
- Intervention (Dietary supplement)
- Standardized Meals
- Intervention (Other)
- Exercise capacity VO2 maximum determination
- Lead sponsor
- University of Alabama at Birmingham
- Collaborator
- National Heart, Lung, and Blood Institute (NHLBI)
Record details
- Record id
cardio:ct-nct04055428- Content hash
ecf4687421f105b9db0ecf78fa5e9627891f30c3b7f1ea9eaa158f00aacea928